VanEck Biotech ETF
BBH
68 hedge funds and large institutions have $217M invested in VanEck Biotech ETF in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 8 closing their positions.
125% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 8
56% more call options, than puts
Call options by funds: $4.07M | Put options by funds: $2.62M
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
42% more capital invested
Capital invested by funds: $153M → $217M (+$63.6M)
15% more funds holding
Funds holding: 59 → 68 (+9)
6.77% more ownership
Funds ownership: 28.89% → 35.66% (+6.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$37.8M |
| 2 |
Morgan Stanley
New York
|
+$11.5M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.36M |
| 4 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$3.31M |
| 5 |
AP
Advisors Preferred
Rockville,
Maryland
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$20.3M |
| 2 |
AFG
Albion Financial Group
Salt Lake City,
Utah
|
-$1.31M |
| 3 |
CM
Churchill Management
Los Angeles,
California
|
-$814K |
| 4 |
SG Americas Securities
New York
|
-$498K |
| 5 |
Jane Street
New York
|
-$415K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Parallax Volatility Advisers
San Francisco,
California
| – | +$113 | +1 | New |
|
BBH Hedge Fund Activity: Q4 2014 in Review
68 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in VanEck Biotech ETF (BBH) for Q4 2014, worth a combined $217M — up 42% from $153M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new BBH positions and 8 closed out — a net gain of 10 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $37.8M. The largest seller was Credit Suisse, cutting an estimated $20.3M.
- 68 institutional investors held VanEck Biotech ETF (BBH) as of Q4 2014, up from 59 in Q3 2014.
- Funds reported $217M of VanEck Biotech ETF stock for Q4 2014, up 42% quarter-over-quarter.
- 18 funds opened new VanEck Biotech ETF positions in Q4 2014 and 8 closed out, a net change of +10 holders.
- The largest VanEck Biotech ETF buyer in Q4 2014 was Goldman Sachs, an estimated $37.8M added.
- The largest VanEck Biotech ETF seller in Q4 2014 was Credit Suisse, an estimated $20.3M sold.
Based on aggregated 13F filings for Q4 2014.